Cue Biopharmaâ„¢ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects.
We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platformâ„¢. This flexibility could truncate the drug selection and ...
Cue Biopharmaâ„¢ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects.
We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platformâ„¢. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs.
Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
-
Number of Employees:
0-25
-
Annual Revenue:
$0-1 Million